InsiderTrades

Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC

Accepted 2024-06-14 00:00:00 ET · period of report 2024-06-12 · accession 0001127602-24-018715 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-06-14 2024-06-12 BCRX HEGGIE THERESA Dir A - Grant $0.00 +6,820 59.5K +13% $0
D 2024-06-14 2024-06-14 BCRX HEGGIE THERESA Dir S - Sale $6.11 -6,698 52.9K -11% -$40.9K
D 2024-06-14 2024-06-12 BCRX HEGGIE THERESA Dir A - Grant $0.00 +49.9K 49.9K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-06-12 A A 6,820 $0.00 59,550 D — — (F1) Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
2 Common Common Stock 2024-06-14 S D 6,698 $6.11 52,852 D — — (F2) These shares were sold with the sole purpose of generating sufficient proceeds to cover the tax liability incurred in connection with the vesting of 16,745 Restricted Stock Units on June 13, 2024. (F3) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.08 to $6.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
3 Derivative Automatic Stock Option Grant 2024-06-12 A A 49,933 $0.00 49,933 D $6.30 · 2025-06-12 to 2034-06-12 49,933 Common Stock (F4) Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.